BOC Sciences Offers Inhibitor Eribulin for Breast Cancer Research

SHIRLEY, NY, NY, UNITED STATES - Jul 30, 2019 - The world's leading chemical vendor BOC Sciences announces at its headquarter in New York to release a featuring inhibitor chemical - eribulin - for researchers who are involved with breast cancer research in the pharmaceutical industry.

Breast cancer is the second most commonly diagnosed cancer in U.S. women, just after skin cancer, which affects one in eight women who live to the age of 80. The disease was due to the uncontrollable mutation and multiplication of breast cells, and cancerous cells may spread to other parts of the body if untreated. Eribulin is a recommended treatment option for locally advanced or metastatic breast cancer in adults whose disease has progressed after at least two chemotherapy regimens.

"Eribulin is another form of halichondrin B made in lab. It is a substance derived from a sea sponge. Similar to some other chemotherapy drugs, eribulin targets the protein tubulin in cells, although it binds to tubulin in a different way and interferes with cancer cell division and growth,” says Mr. Barron Jones, the Marketing Chief of BOC Sciences. “According to the results of a phase III clinical trial, treatment with eribulin can greatly improve overall survival in women with metastatic breast cancer whose disease progressed despite multiple rounds of chemotherapy previously. In view of these findings, last November FDA approved eribulin for the treatment of patients with metastatic disease who have already undergone at least two prior chemotherapy regimens.”

In the clinical trial, 762 patients were randomly assigned to receive either eribulin or other therapies recommended by the physicians. The results showed that women who received eribulin lived 2.5 months longer on average than those who are treated with their physician's choice, which is 13.1 months versus 10.6 months.

"Currently, eribulin is used in the USA, Europe and other countries worldwide for the treatment of patients with advanced or MBC who are refractory to other treatments,” further explains Mr. Jones. “A few other similar trials are also carried out to test the efficacy of this inhibitor drug. Nearly all come to the conclusion that eribulin is an effective and safe therapeutic option in heavily pretreated patients with aBC.” However, side effects still exist. More researches are needed as to how to reduce the side effects without compromising to efficacy.

Small molecule inhibitors are already a well-established class of potential useful drugs, which attracts numerous attention from researchers engaged in various fields such as neurological disease, cancer, metabolic disease and so on. To know more about eribulin or other inhibitors, please visit https://www.bocsci.com/inhibitor-list-84.html.

About BOC Sciences

BOC Sciences’ inhibitor offering is quite wide-ranged, including PDK-1 inhibitor, PGE Synthase inhibitor, PDGFR inhibitor, PKD inhibitor, RAD51 inhibitor, Ribosomal S6 Kinase inhibitor, and more. For more specific needs, just contact us at account@bocsci.com.